Eli Lilly & Co. Archives - Medical Design Sourcing

Eli Lilly to acquire cardiometabolic disease treatment maker Versanis for $1.925B

Eli Lilly (NYSE:LLY) announced today that it entered into a definitive agreement to acquire Versanis, a private, clinical stage biopharmaceutical company.

Versanis focuses on the development of new medicines for the treatment of cardiometabolic diseases. Its lead asset, bimagumab, is a monoclonal antibody. Bimagumab binds activin type II A and B receptors to block activin and myostatin signaling. The company currently has it under assessment in the BELIEVE Phase 2b study alone and in combination with semaglutide. It aims to treat overweight or obese adults.

According to a news release, combining incretins with bimagrumab could potentially reduce fat mass while preserving muscle mass. It may lead to better outcomes for people with obesity and obesity-related complications.

“Lilly is committed to investigating potential new medicines to fight cardiometabolic diseases, including obesity, a chronic disease that affects over 100 million Americans,”…

Lilly completes acquisition of Akouos

Eli Lilly and Company (NYSE:LLY) announced today that it successfully completed its acquisition of Akouos (Nasdaq:AKUS).

Indianpolis-based Eli Lilly’s acquisition expands its efforts in genetic medicines. Akouos offers a portfolio of potential first-in-class adeno-associated viral gene therapies. The gene therapies treat inner ear conditions, including sensorineural hearing loss.

The company initially announced the acquisition in October. At the time, it said it would pay $487 million upfront, plus a contingent value right for an aggregate amount up to approximately $610 million.

“Akouos brings more top-tier talent and an important pipeline to Lilly’s Institute for Genetic Medicine that will further accelerate our work to advance genetic medicines for people living with difficult-to-treat diseases,” said Andrew C. Adams, SVP of genetic medicine at Lilly and co-director of the Institute for Genetic Medicine. “We look forward …

Glooko adds former Eli Lilly exec to its board of directors

Diabetes management technology developer Glooko announced today that it appointed Alfonso “Chito” Zulueta to its board of directors.

Zulueta joins Palo Alto, California-based Glooko’s board having spent more than 30 years with Eli Lilly and Company, serving as a senior executive across an array of global business and commercial units.

Get the full story at our sister site, Drug Delivery Business News.

Eli Lilly to build $1B manufacturing facility for injectable products, devices in North Carolina

Eli Lilly (NYSE:LLY) announced today that it plans to invest more than $1 billion to create a new manufacturing site in North Carolina.

Indianapolis-based Eli Lilly’s new facility, which it expects to bring with it nearly 600 jobs in Concord, North Carolina, will manufacture parenteral (injectable) products and devices while increasing the company’s manufacturing capacity.

Get the full story at our sister site, Drug Delivery Business News.

How some diabetes tech companies are honoring National Diabetes Month

World Diabetes Day (Nov. 14) may have passed, but it remains National Diabetes Month through the end of November.

A number of companies developing some of the most intriguing innovations in diabetes care have also stepped forward this month to organize awareness-raising efforts for the metabolic disease.

Here are some steps a handful of diabetes technology developers have made to try and bring more attention to diabetes management:

Get the full story at our sister site, Drug Delivery Business News.

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those with diabetes.

This year, that aim remains the same, and medical technology companies continue to look for ways to continue improving the management of the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains a vital part of the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists involved in discovering insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for managing and treating diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

7 diabetes treatment innovations to look out for on World Diabetes Day

World Diabetes Day — Nov. 14 — centers around raising awareness for those who live every day with diabetes.

This year, that aim remains the same, and medical technology companies all over the world continue to look for ways to help manage the metabolic disease.

Some of those treatments involve insulin, which was discovered as a treatment for diabetes in 1922 and remains the standard of care. World Diabetes Day falls on Nov. 14 because it is the birthday of Frederick Banting, one of the scientists who helped to discover insulin as a treatment for diabetes.

However, while many medtech companies look for ways to make insulin accessible and efficient in treating diabetes, others are innovating treatment avenues outside of insulin. Regardless of the path chosen, all have created intriguing options for helping to manage and treat diabetes. Here are seven innovations in diabetes treatment that are worth keeping an eye on:

Next>>

Eli Lilly touts data for tirzepatide compared to insulin glargine for type 2 diabetes

Eli Lilly (NYSE:LLY) announced positive results from a trial comparing tirzepatide to titrated insulin glargine in adults with type 2 diabetes.

Indianapolis-based Eli Lilly’s Surpass-4 clinical trial demonstrated that adults with type 2 diabetes and increased cardiovascular (CV) risk experienced superior A1C and body weight reductions from baseline across all three doses of tirzepatide compared to titrated insulin glargine.

Get the full story at our sister site, Drug Delivery Business News.

How Lilly Oncology is aiming to improve clinical trial diversity

Minorities tend to participate in clinical trials at far lower rates than their real-world demographics and prevalence of the disease, according to the American Society of Clinical Oncology. In addition, minorities often have worse outcomes for certain cancers than the broader public. For instance, the mortality rate for Black women with breast cancer is 40% higher than that of white women.

The pandemic, however, has highlighted persistent health disparities while offering potential strategies for improvement, according to Amy Davis, senior director of clinical development at Lilly Oncology.

The pandemic has popularized the use of decentralized trials. For instance, Lilly debuted decentralized capabilities in a recent breast cancer trial and will continue doing so for upcoming trials. “We are building in decentralized capabilities from the get-go — decreasing the number of in-person visits by half,” Davis said. The company is using remote data capture and offer…

Eli Lilly to donate nearly $1M to Type 1 diabetes initiative

Eli Lilly (NYSE:LLY) announced today that it will commit nearly $1 million over the next three years toward helping children with type 1 diabetes.

Indianapolis-based Eli Lilly, in a joint effort with the Leona M. and Harry B. Helmsley Charitable Trust, seeks to promote greater access to care and resources while inspiring confidence for children living with Type 1 diabetes through the Type 1 Diabetes Camps Initiative.

Get the full story at our sister site, Drug Delivery Business News.

Eli Lilly forms neuroscience and immunology units amid leadership changes

Eli Lilly (NYSE:LLY) today announced executive leadership changes as it creates neuroscience and immunology business units.

Indianapolis-based Eli Lilly split its bio-medicines segment into Lilly Neuroscience and Lilly Immunology in the organizational shift, to be made effective Sep. 5, with Anne White set to lead the neuroscience unit and Patrik Jonsson set to head up the immunology arm.

Get the full story at our sister site, Drug Delivery Business News.

FDA approves, expands label for Eli Lilly’s rapid-acting insulin for infusion

Eli Lilly (NYSE:LLY) announced today that it received FDA approval and expanded labeling for its Lyumjev rapid-acting insulin.

Indianapolis-based Eli Lilly’s Lyumjev (insulin lispro-aabc injection) 100 units/mL holds indication to improve glycemic control in adults with type 1 and type 2 diabetes, including administration via continuous subcutaneous insulin infusion (CSII) with an insulin pump.

Get the full story at our sister site, Drug Delivery Business News.